BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16874014)

  • 21. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
    Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
    Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
    Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
    Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
    Kivivuori SM; Riikonen P; Valanne L; Lönnqvist T; Saarinen-Pihkala UM
    Acta Paediatr; 2011 Jan; 100(1):134-8. PubMed ID: 20712831
    [No Abstract]   [Full Text] [Related]  

  • 26. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
    El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
    J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
    Choi LM; Rood B; Kamani N; La Fond D; Packer RJ; Santi MR; Macdonald TJ
    Pediatr Blood Cancer; 2008 May; 50(5):970-5. PubMed ID: 17941070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
    Kushner BH; Kramer K; Modak S; Cheung NK
    J Clin Oncol; 2006 Nov; 24(33):5271-6. PubMed ID: 17114661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metronomic chemotherapy: a new approach in cancer therapy].
    Bujak A; Kałas W
    Postepy Hig Med Dosw (Online); 2008 Jul; 62():364-71. PubMed ID: 18688207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.
    Coleman M; Martin P; Ruan J; Furman R; Niesvizky R; Elstrom R; George P; Kaufman TP; Leonard JP
    Cancer; 2008 May; 112(10):2228-32. PubMed ID: 18338745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
    Porkholm M; Valanne L; Lönnqvist T; Holm S; Lannering B; Riikonen P; Wojcik D; Sehested A; Clausen N; Harila-Saari A; Schomerus E; Thorarinsdottir HK; Lähteenmäki P; Arola M; Thomassen H; Saarinen-Pihkala UM; Kivivuori SM
    Pediatr Blood Cancer; 2014 Sep; 61(9):1603-9. PubMed ID: 24692119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective experience of children with relapsed brain tumors treated with oral combination of axitinib and metronomic etoposide.
    Donzé C; Revon-Rivière G; Pondrom M; Verschuur A; Leblond P; André N
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31076. PubMed ID: 38778441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
    Fousseyni T; Diawara M; Pasquier E; André N
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.